Emerging Drug Toxicities of Highly Active Antiretroviral Therapy for HumanImmunodeficiency Virus (HIV) Infection

By  

Current Drug Targets, Vol. 4, Iss. 1, 2003-01 ,pp. : 13-22

Bentham Science Publishers

Access to resources Recommend Favorite

A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061

By Rudek Michelle A.   Moore Page C.   Mitsuyasu Ronald T.   Dezube Bruce J.   Aboulafia David   Gerecitano John   Sullivan Ryan   Cianfrocca Mary E.   Henry David H.   Ratner Lee   Haigentz Missak   Dowlati Afshin   Little Richard F.   Ivy Susan Percy   Deeken John F.  

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1194-1202

Blackwell Publishing

Access to resources Recommend Favorite

Computational Analysis of Human Immunodeficiency Virus (HIV) Type-1 Reverse Transcriptase Crystallographic Models Based on Significant Conserved Residues Found in Highly Active Antiretroviral Therapy (HAART)-Treated Patients (Supplementary Material)

By  

Current Medicinal Chemistry, Vol. 17, Iss. 4, 2010-02 ,pp. : 290-308

Bentham Science Publishers

Access to resources Recommend Favorite

Antiretroviral Therapy Does Not Block the Secretion of the Human Immunodeficiency Virus Tat Protein

By  

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 12, Iss. 1, 2012-02 ,pp. : 81-86

Bentham Science Publishers

Access to resources Recommend Favorite

Does mitochondrial dysfunction during antiretroviral therapy in human immunodeficiency virus infection suggest antioxidant supplementation as a beneficial option?

By Gil Lizette   Pérez Daniel   Tápanes Rolando   Pérez Jorge   Grune Tilman  

Redox Report, Vol. 10, Iss. 3, 2005-06 ,pp. : 113-119

Maney Publishing

Access to resources Recommend Favorite